Clarity enters a Commercial Manufacturing Agreement
Filed with ASX · · 4 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging
- SABRE topline results
- DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.
- DISCO topline results
- First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT
Later from Clarity Pharmaceuticals
- Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
- Co-PSMA trial recruitment successfully completed
- Clarity successfully completes $203 million institutional pl
- Preliminary Final Report
- S&P DJI Announces September 2025 Quarterly Rebalance
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals